International News
Europe close: Stocks jump amid mixed readings on investor sentiment
Stocks on the Continent finished higher on the back of an unexpectedly strong reading on analyst sentiment towards Germany, helped by some positive headlines around Brexit and US-China trade talks.
US open: Dow on track for fifth straight day of gains
US stocks opened higher on Tuesday as investors eyed the start of the Federal Reserve's two-day policy meeting.
FCA fines UBS £27.6m for dire reporting of deals
The City watchdog has fined UBS more than £27m for failing to keep proper records on nearly 136m transactions over a decade.
Asia report: Markets mixed as investors look to Fed
Markets in Asia finished in a mixed state on Tuesday, as investors closed their wallets ahead of this month’s Federal Reserve meeting in the United States.
Investors sue Danske Bank for $475m over money laundering
Institutional investors are suing Danske Bank for $475m of damages in connection with the money laundering scandal that hit the Danish bank last year.
Jones Lang LaSalle to buy HFF in $2bn deal
Jones Lang LaSalle has agreed to buy capital markets services provider HFF in a cash and stock deal worth about $2bn.
ECB scepticism could threaten Deutsche-Commerzbank deal
Deutsche Bank’s mooted merger with Commerzbank could face opposition from the European Central Bank after the eurozone’s leading financial supervisor said he disliked the idea of national banking champions.
US pre-open: Stocks to rise as Fed kicks off policy meeting
US stocks looked set for a positive open on Tuesday as investors eyed the start of the Federal Reserve's two-day policy meeting.
Roche gets FDA approval for Tecentriq chemotherapy combination
Roche announced on Tuesday that the US Food and Drug Administration (FDA) has approved ‘Tecentriq’ (atezolizumab), in combination with carboplatin and etoposide chemotherapy, for the initial treatment of adults with extensive-stage small cell lung cancer.
Tilray revenues and losses widen in fourth quarter
Canadian marijuana outfit Tilray posted a wider than expected fourth-quarter loss even though revenues were bigger than forecast.